

Special Issue

B and T Cell-Mediated Immunity 2.0

Message from the Guest Editors

Generation of vigorous cell-mediated immune responses is critical to protection against many infectious diseases. T cells and B cells represent separate but interconnected arms of the adaptive immune response. As such, they are critical in providing long-lasting protection, thanks to the induction of immune memory, following vaccination or natural infection. This Special Issue focuses on T and B cell-mediated immunity as they relate to vaccination and protection against infectious diseases. The goal is to enhance our knowledge of the important roles that T and B cells play to provide long-lasting protection. Understanding the contributions of T and B cells, as well as their interactions, following vaccination and/or natural infection could provide critical insights that will help further vaccine development.

Guest Editors

Dr. Monica A. McArthur

Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA

Dr. Franklin Toapanta

Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA

Deadline for manuscript submissions

closed (30 June 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/71415

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).